An open label trial of folate receptor-targeted intraoperative molecular imaging to localize pulmonary squamous cell carcinomas
Oncotarget2018Vol. 9(17), pp. 13517–13529
Citations Over TimeTop 10% of 2018 papers
Jarrod D. Predina, Andrew D. Newton, Leilei Xia, Christopher Corbett, Courtney Connolly, Michael Shin, Lydia Frezel Sulyok, Leslie A. Litzky, Charuhas Deshpande, Shuming Nie, Sumith A. Kularatne, Philip S. Low, Sunil Singhal
Abstract
This work demonstrates that FR-IMI is potentially feasible in 70% of SCC patients, and that molecular imaging can improve localization during minimally invasive pulmonary resection. These findings complement previous data demonstrating that ∼98% of pulmonary adenocarcinomas are localized during FR-IMI and suggest broad applicability for NSCLC patients undergoing resection.
Related Papers
- 99mTc-HYNIC-folate: a novel receptor-based targeted radiopharmaceutical for tumor imaging.(1999)
- → γ-Cyclodextrin–folate complex-functionalized quantum dots for tumor-targeting and site-specific labeling(2011)25 cited
- → Indications for Thoracotomy: Deciding to Operate(1989)45 cited
- → Folate receptor-mediated targeted polymeric gadolinium complexes for magnetic resonance imaging in pulmonary tumor xenografts(2012)5 cited
- [Folate-poly-L-lysine-Gd-DTPA as MR contrast agent for tumor imaging via folate receptor-targeted delivery].(2007)